4.7 Article

Vascular Dysfunction in Obstructive Sleep Apnea and Type 2 Diabetes Mellitus

Journal

OBESITY
Volume 19, Issue 1, Pages 17-22

Publisher

WILEY
DOI: 10.1038/oby.2010.116

Keywords

-

Funding

  1. AHA
  2. National Sleep Foundation
  3. American Sleep Medicine Foundation
  4. Philips
  5. Sepracor
  6. NMT
  7. Apnex
  8. Itamar
  9. Pfizer
  10. SGS
  11. Medtronic
  12. Ethicon
  13. Cephalon
  14. SHC
  15. [K24 HL 093218]
  16. [R01 HL090897-01]
  17. [R01 HL085188-01]
  18. [R01 HL73146]
  19. [R01-HL075678]
  20. [R01 DK076937]
  21. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073146, R01HL085188, K24HL093218, R01HL090897, R01HL075678] Funding Source: NIH RePORTER
  22. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076937] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Despite the high prevalence of obstructive sleep apnea (OSA) in type 2 diabetes mellitus (DM), the attributable vascular risk from each condition is unknown. We hypothesize that OSA may have a similar effect on vascular function as type 2 diabetes does. Healthy normal-weight subjects, healthy obese subjects, subjects with type 2 diabetes, and obese subjects with OSA were enrolled. Vascular function was assessed with brachial artery ultrasound for flow-mediated dilatation (FMD) and in skin microcirculation by laser Doppler flowmetry. One hundred fifty-three subjects were studied: healthy normal-weight controls (NCs) (n = 14), healthy obese controls (OCs) (n = 33), subjects with DM (n = 68), and obese subjects with OSA (n = 38). The DM group did not undergo sleep study and thus may have had subclinical OSA. The OSA and type 2 diabetes groups had impaired FMD as compared to both the normal-weight and OC groups (5.8 +/- 3.8%, 5.4 +/- 1.6% vs. 9.1 +/- 2.5%, 8.3 +/- 5.1%, respectively, P < 0.001, post hoc Fischer test). When referenced to the NC group, a multiple linear regression model adjusting for covariates found that baseline brachial artery diameter (beta = -3.75, P < 0.001), OSA (beta = -2.45, P = 0.02) and type 2 diabetes status (beta = -2.31, P = 0.02), negatively predicted % FMD. OSA status did not seem to affect nitroglycerin-induced vasodilation (endothelium-independent) of the brachial artery or vascular function in the skin microcirculation. OSA impairs endothelial function in the brachial artery to a similar degree as type 2 diabetes does. OSA, however, does not appear to affect brachial endothelium-independent vasodilation or skin microcirculatory function. Treatment of OSA in patients with concomitant type 2 diabetes, therefore, may be a potential therapeutic option to improve macro-, but not microvascular outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available